<DOC>
	<DOCNO>NCT02152553</DOCNO>
	<brief_summary>The investigator show patient adrenal insufficiency ( Addison 's disease ) , rare disorder , double expect mortality rate Sweden despite Standard Care glucocorticoid ( GC ) replacement . One % Swedish population , however , receive GCs inflammatory disease , management empirical adjust underlying disease activity . The desired anti-inflammatory therapeutic effect differentiate adverse metabolic ( osteoporosis , obesity , diabetes mellitus ) immunosuppressive side effect GC . This frequently result suboptimal GC therapy adverse effect due over-dosing poor efficacy due under-dosing . The primary aim identify biomarker metabolic effect GCs . Patients Addison 's disease completely lack endogenous GCs therefore consider human GC knock-out model . They therefore study near-physiological exposure GC starvation . This uniquely allow clean biomarker identification model ( use transcriptomics , proteomics metabolomics ) . The secondary aim validate candidate biomarker ( ) dose-response study use patient population . A biomarker GC action make possible individualised therapy pharmacological GC treatment . It would allow GC replacement monitor Addison 's disease could become specific diagnostic tool patient GC deficiency excess ( Cushings syndrome ) .</brief_summary>
	<brief_title>Biomarker ( ) Glucocorticoids</brief_title>
	<detailed_description />
	<mesh_term>Addison Disease</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<criteria>Primary adrenal insufficiency stable glucocorticoid replacement therapy ( 1530 mg Hydrocortisone stable dose last 3 month ) due autoimmune adrenalitis ( disease diagnose least 12 month inclusion ) , age 2060 year , BMI 2030 kg/m2 , ability comply protocol procedure . Glucocorticoid replacement therapy indication primary adrenal treatment , treatment sex hormone inclusive contraceptive drug , treatment levothyroxine , diabetes mellitus , renal liver failure , significant symptomatic cardiovascular disease .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Biomarker</keyword>
	<keyword>Glucocorticoids</keyword>
	<keyword>Metabolism</keyword>
	<keyword>Pharmacology</keyword>
	<keyword>Metabolomics</keyword>
</DOC>